对2型糖尿病患者使用噻唑烷二酮与痴呆风险之间关系的评论

IF 3 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Houyu Zhao, Lin Zhuo, Yexiang Sun, Peng Shen, Hongbo Lin, Siyan Zhan
{"title":"对2型糖尿病患者使用噻唑烷二酮与痴呆风险之间关系的评论","authors":"Houyu Zhao,&nbsp;Lin Zhuo,&nbsp;Yexiang Sun,&nbsp;Peng Shen,&nbsp;Hongbo Lin,&nbsp;Siyan Zhan","doi":"10.1111/1753-0407.13408","DOIUrl":null,"url":null,"abstract":"<p>We thank Wasif et al for their comments<span><sup>1</sup></span> on our article that explored the association between thiazolidinedione (TZD) use and dementia risk in patients with type 2 diabetes mellitus (T2DM).<span><sup>2</sup></span> In their letter, the authors addressed the potential confounding effects of age of diabetes onset and mental disorders, which were suggested to be associated with dementia risk in recent studies,<span><sup>3, 4</sup></span> and thus they suggested subgroup analyses according to participants' age at T2DM onset and status of mental disorders.<span><sup>1</sup></span> In our analyses we controlled age and years of T2DM at baseline<span><sup>2</sup></span>; thus the issue of collinearity would arise in the multivariate and inverse probability weighted model if we controlled age of T2DM onset, which was the difference between baseline age and diabetes duration. Moreover, comorbidities were adjusted using the Charlson comorbidity index, which did not contain mental disorders.<span><sup>2</sup></span></p><p>In response to the authors' concerns, we conducted subgroup analyses according to their suggestions<span><sup>1</sup></span> (Table 1). Age of diabetes onset was defined as the age when the patient was first diagnosed with T2DM. In addition, history of mental disorders was identified using the <i>International Classification of Diseases, Tenth Revision</i> (all codes of F10–F99 except F70–F79) according to a previous study.<span><sup>4</sup></span> Consistent with previous studies, we observed higher incidence of dementia in patients of older age and with history of mental disorders.<span><sup>3, 4</sup></span> But no significant effect modification was observed. Compared with use of alpha-glucosidase inhibitors, TZD use was significantly associated with dementia incidence in different age groups, with a hazard ratio (HR) of 0.44 (95% confidence interval [CI], 0.21–0.91), 0.62 (95% CI, 0.39–0.98), and 0.47 (95% CI, 0.31–0.71) for T2DM patients aged &lt;55 years, 55–65 years, and &gt;65 years, respectively. Similarly, TZD use was consistently associated with dementia risk in terms of history of mental disorders, with an HR of 0.53 (95% CI, 0.30–0.94) and 0.50 (95% CI, 0.36–0.69) for T2DM patients with and without history of any mental disorders, respectively.</p><p>We agree with the authors that we cannot fully rule out biases caused by unmeasured confounding and inaccurate information.<span><sup>5</sup></span> Therefore, we conducted several sensitivity analyses using different dementia identification rules combing diagnosis and prescriptions of antidementia drugs. Results under various outcome definitions were consistent (the Table 1), suggesting that our results were robust against potential outcome misclassification.<span><sup>2</sup></span> Furthermore, we did not adjust full medication history and some other potential confounders, such as dietary patterns, hence we calculate the E-value as a sensitivity analysis. The E-value for the observed HR of 0.51 in our primary analysis was 3.33, which was the minimum strength that an unmeasured confounder needed to be associated with both the exposure and outcome to explain away the observed association.<span><sup>2</sup></span></p><p>However, our analyses should be interpreted in the context of its observational nature. Future prospective studies with more refined measurement of dementia cases and potential confounders are needed to give further insights into the potential role of TZDs in reducing dementia incidence.</p><p>Houyu Zhao conceived of and designed the work. Hongbo Lin, Peng Shen, and Yexiang Sun acquired the data. Houyu Zhao analyzed the data. Houyu Zhao drafted the manuscript. Lin Zhuo and Siyan Zhan critically revised the manuscript for important intellectual content. Siyan Zhan, Hongbo Lin, and Peng Shen supervised the study. Houyu Zhao and Siyan Zhan obtained the funding. All authors were responsible for the interpretation of the data, and revised, and gave final approval of the manuscript. Siyan Zhan is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p>This work was supported by a grant from the China Postdoctoral Science Foundation (Grant No. 2022M710251) and a grant from the National Natural Science Foundation of China (Grant No. 81973146). The funder had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or decision to submit the article for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit the article for publication.</p><p>The authors have no conflicts of interest to declare.</p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"15 7","pages":"629-631"},"PeriodicalIF":3.0000,"publicationDate":"2023-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13408","citationCount":"0","resultStr":"{\"title\":\"Response to: Critical commentary on the association between thiazolidinedione use and dementia risk in patients with type 2 diabetes\",\"authors\":\"Houyu Zhao,&nbsp;Lin Zhuo,&nbsp;Yexiang Sun,&nbsp;Peng Shen,&nbsp;Hongbo Lin,&nbsp;Siyan Zhan\",\"doi\":\"10.1111/1753-0407.13408\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>We thank Wasif et al for their comments<span><sup>1</sup></span> on our article that explored the association between thiazolidinedione (TZD) use and dementia risk in patients with type 2 diabetes mellitus (T2DM).<span><sup>2</sup></span> In their letter, the authors addressed the potential confounding effects of age of diabetes onset and mental disorders, which were suggested to be associated with dementia risk in recent studies,<span><sup>3, 4</sup></span> and thus they suggested subgroup analyses according to participants' age at T2DM onset and status of mental disorders.<span><sup>1</sup></span> In our analyses we controlled age and years of T2DM at baseline<span><sup>2</sup></span>; thus the issue of collinearity would arise in the multivariate and inverse probability weighted model if we controlled age of T2DM onset, which was the difference between baseline age and diabetes duration. Moreover, comorbidities were adjusted using the Charlson comorbidity index, which did not contain mental disorders.<span><sup>2</sup></span></p><p>In response to the authors' concerns, we conducted subgroup analyses according to their suggestions<span><sup>1</sup></span> (Table 1). Age of diabetes onset was defined as the age when the patient was first diagnosed with T2DM. In addition, history of mental disorders was identified using the <i>International Classification of Diseases, Tenth Revision</i> (all codes of F10–F99 except F70–F79) according to a previous study.<span><sup>4</sup></span> Consistent with previous studies, we observed higher incidence of dementia in patients of older age and with history of mental disorders.<span><sup>3, 4</sup></span> But no significant effect modification was observed. Compared with use of alpha-glucosidase inhibitors, TZD use was significantly associated with dementia incidence in different age groups, with a hazard ratio (HR) of 0.44 (95% confidence interval [CI], 0.21–0.91), 0.62 (95% CI, 0.39–0.98), and 0.47 (95% CI, 0.31–0.71) for T2DM patients aged &lt;55 years, 55–65 years, and &gt;65 years, respectively. Similarly, TZD use was consistently associated with dementia risk in terms of history of mental disorders, with an HR of 0.53 (95% CI, 0.30–0.94) and 0.50 (95% CI, 0.36–0.69) for T2DM patients with and without history of any mental disorders, respectively.</p><p>We agree with the authors that we cannot fully rule out biases caused by unmeasured confounding and inaccurate information.<span><sup>5</sup></span> Therefore, we conducted several sensitivity analyses using different dementia identification rules combing diagnosis and prescriptions of antidementia drugs. Results under various outcome definitions were consistent (the Table 1), suggesting that our results were robust against potential outcome misclassification.<span><sup>2</sup></span> Furthermore, we did not adjust full medication history and some other potential confounders, such as dietary patterns, hence we calculate the E-value as a sensitivity analysis. The E-value for the observed HR of 0.51 in our primary analysis was 3.33, which was the minimum strength that an unmeasured confounder needed to be associated with both the exposure and outcome to explain away the observed association.<span><sup>2</sup></span></p><p>However, our analyses should be interpreted in the context of its observational nature. Future prospective studies with more refined measurement of dementia cases and potential confounders are needed to give further insights into the potential role of TZDs in reducing dementia incidence.</p><p>Houyu Zhao conceived of and designed the work. Hongbo Lin, Peng Shen, and Yexiang Sun acquired the data. Houyu Zhao analyzed the data. Houyu Zhao drafted the manuscript. Lin Zhuo and Siyan Zhan critically revised the manuscript for important intellectual content. Siyan Zhan, Hongbo Lin, and Peng Shen supervised the study. Houyu Zhao and Siyan Zhan obtained the funding. All authors were responsible for the interpretation of the data, and revised, and gave final approval of the manuscript. Siyan Zhan is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p>This work was supported by a grant from the China Postdoctoral Science Foundation (Grant No. 2022M710251) and a grant from the National Natural Science Foundation of China (Grant No. 81973146). The funder had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or decision to submit the article for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit the article for publication.</p><p>The authors have no conflicts of interest to declare.</p>\",\"PeriodicalId\":189,\"journal\":{\"name\":\"Journal of Diabetes\",\"volume\":\"15 7\",\"pages\":\"629-631\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2023-05-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13408\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Diabetes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/1753-0407.13408\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1753-0407.13408","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

我们的文章探讨了2型糖尿病(T2DM)患者使用噻唑烷二酮(TZD)与痴呆风险之间的关系,感谢Wasif等人对这篇文章的评论在他们的信中,作者指出了糖尿病发病年龄和精神障碍的潜在混淆效应,这在最近的研究中被认为与痴呆风险有关,3,4因此他们建议根据参与者的年龄和精神障碍状态进行亚组分析在我们的分析中,我们将T2DM患者的年龄和年龄控制在基线2;因此,如果我们控制T2DM发病年龄(即基线年龄与糖尿病病程之间的差异),那么多变量和逆概率加权模型中就会出现共线性问题。此外,使用Charlson合并症指数对合并症进行调整,该指数不包括精神障碍。2针对作者的担忧,我们根据他们的建议进行了亚组分析1(表1)。糖尿病发病年龄定义为患者首次诊断为2型糖尿病的年龄。此外,根据先前的研究,使用国际疾病分类第十版(除F70-F79外,所有代码为F10-F99)确定精神障碍史与先前的研究一致,我们观察到老年痴呆患者和有精神障碍史的患者发病率更高。3,4但未观察到明显的效果改变。与使用α -葡萄糖苷酶抑制剂相比,使用TZD与不同年龄组的痴呆发病率显著相关,55岁、55 - 65岁和65岁T2DM患者的风险比(HR)分别为0.44(95%可信区间[CI], 0.21-0.91)、0.62 (95% CI, 0.39-0.98)和0.47 (95% CI, 0.31-0.71)。同样,就精神障碍史而言,TZD的使用始终与痴呆风险相关,有和没有任何精神障碍史的T2DM患者的HR分别为0.53 (95% CI, 0.30-0.94)和0.50 (95% CI, 0.36-0.69)。我们同意作者的观点,即我们不能完全排除由未测量的混杂和不准确的信息引起的偏差因此,我们结合诊断和抗痴呆药物处方,采用不同的痴呆识别规则进行了敏感性分析。不同结局定义下的结果是一致的(表1),表明我们的结果对于潜在的结局错误分类是稳健的此外,我们没有调整完整的用药史和一些其他潜在的混杂因素,如饮食模式,因此我们计算e值作为敏感性分析。在我们的初步分析中,观察到的HR为0.51的e值为3.33,这是与暴露和结果相关联的未测量混杂因素需要的最小强度,以解释所观察到的关联。然而,我们的分析应该在其观测性质的背景下进行解释。未来的前瞻性研究需要对痴呆病例和潜在混杂因素进行更精确的测量,以进一步了解tzd在降低痴呆发病率方面的潜在作用。赵厚玉构思并设计了这个作品。林洪波、沈鹏和孙业祥获得了数据。赵厚宇分析了这些数据。赵厚玉起草了手稿。林卓和詹思燕对手稿中重要的知识内容进行了批判性的修改。詹思燕、林洪波和沈鹏监督了这项研究。赵厚玉和詹思燕获得了资助。所有作者负责对数据进行解读、修改,并对稿件给予最终批复。詹思燕是这项工作的担保人,因此,她对研究中的所有数据有完全的访问权,并对数据的完整性和数据分析的准确性负责。中国博士后科学基金(批准号:2022M710251)和国家自然科学基金(批准号:81973146)资助。资助者在研究设计、数据收集、数据分析、数据解释、撰写报告或决定是否提交文章发表方面没有任何作用。通讯作者对研究中的所有数据拥有完全的访问权,并对文章是否发表的决定负有最终责任。作者无利益冲突需要申报。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Response to: Critical commentary on the association between thiazolidinedione use and dementia risk in patients with type 2 diabetes

We thank Wasif et al for their comments1 on our article that explored the association between thiazolidinedione (TZD) use and dementia risk in patients with type 2 diabetes mellitus (T2DM).2 In their letter, the authors addressed the potential confounding effects of age of diabetes onset and mental disorders, which were suggested to be associated with dementia risk in recent studies,3, 4 and thus they suggested subgroup analyses according to participants' age at T2DM onset and status of mental disorders.1 In our analyses we controlled age and years of T2DM at baseline2; thus the issue of collinearity would arise in the multivariate and inverse probability weighted model if we controlled age of T2DM onset, which was the difference between baseline age and diabetes duration. Moreover, comorbidities were adjusted using the Charlson comorbidity index, which did not contain mental disorders.2

In response to the authors' concerns, we conducted subgroup analyses according to their suggestions1 (Table 1). Age of diabetes onset was defined as the age when the patient was first diagnosed with T2DM. In addition, history of mental disorders was identified using the International Classification of Diseases, Tenth Revision (all codes of F10–F99 except F70–F79) according to a previous study.4 Consistent with previous studies, we observed higher incidence of dementia in patients of older age and with history of mental disorders.3, 4 But no significant effect modification was observed. Compared with use of alpha-glucosidase inhibitors, TZD use was significantly associated with dementia incidence in different age groups, with a hazard ratio (HR) of 0.44 (95% confidence interval [CI], 0.21–0.91), 0.62 (95% CI, 0.39–0.98), and 0.47 (95% CI, 0.31–0.71) for T2DM patients aged <55 years, 55–65 years, and >65 years, respectively. Similarly, TZD use was consistently associated with dementia risk in terms of history of mental disorders, with an HR of 0.53 (95% CI, 0.30–0.94) and 0.50 (95% CI, 0.36–0.69) for T2DM patients with and without history of any mental disorders, respectively.

We agree with the authors that we cannot fully rule out biases caused by unmeasured confounding and inaccurate information.5 Therefore, we conducted several sensitivity analyses using different dementia identification rules combing diagnosis and prescriptions of antidementia drugs. Results under various outcome definitions were consistent (the Table 1), suggesting that our results were robust against potential outcome misclassification.2 Furthermore, we did not adjust full medication history and some other potential confounders, such as dietary patterns, hence we calculate the E-value as a sensitivity analysis. The E-value for the observed HR of 0.51 in our primary analysis was 3.33, which was the minimum strength that an unmeasured confounder needed to be associated with both the exposure and outcome to explain away the observed association.2

However, our analyses should be interpreted in the context of its observational nature. Future prospective studies with more refined measurement of dementia cases and potential confounders are needed to give further insights into the potential role of TZDs in reducing dementia incidence.

Houyu Zhao conceived of and designed the work. Hongbo Lin, Peng Shen, and Yexiang Sun acquired the data. Houyu Zhao analyzed the data. Houyu Zhao drafted the manuscript. Lin Zhuo and Siyan Zhan critically revised the manuscript for important intellectual content. Siyan Zhan, Hongbo Lin, and Peng Shen supervised the study. Houyu Zhao and Siyan Zhan obtained the funding. All authors were responsible for the interpretation of the data, and revised, and gave final approval of the manuscript. Siyan Zhan is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

This work was supported by a grant from the China Postdoctoral Science Foundation (Grant No. 2022M710251) and a grant from the National Natural Science Foundation of China (Grant No. 81973146). The funder had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or decision to submit the article for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit the article for publication.

The authors have no conflicts of interest to declare.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Diabetes
Journal of Diabetes ENDOCRINOLOGY & METABOLISM-
CiteScore
6.50
自引率
2.20%
发文量
94
审稿时长
>12 weeks
期刊介绍: Journal of Diabetes (JDB) devotes itself to diabetes research, therapeutics, and education. It aims to involve researchers and practitioners in a dialogue between East and West via all aspects of epidemiology, etiology, pathogenesis, management, complications and prevention of diabetes, including the molecular, biochemical, and physiological aspects of diabetes. The Editorial team is international with a unique mix of Asian and Western participation. The Editors welcome submissions in form of original research articles, images, novel case reports and correspondence, and will solicit reviews, point-counterpoint, commentaries, editorials, news highlights, and educational content.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信